분자영상 및 방사화학

본문글자크기
  • [Biomaterials.] Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models via non-invasive fluorescence molecular tomography

    T&R Biofab, KIST / 임승호, 윤홍열, 문성환*, 김광명*

  • 출처
    Biomaterials.
  • 등재일
    2021 Jan
  • 저널이슈번호
    266:120472. doi: 10.1016/j.biomaterials.2020.120472. Epub 2020 Oct 19.
  • 내용

    바로가기  >

    Abstract
    Human embryonic stem cells-derived endothelial progenitor cells (hEPCs) were utilized as cell therapeutics for the treatment of ischemic diseases. However, in vivo tracking of hEPCs for predicting their therapeutic efficacy is very difficult. Herein, we developed bioorthogonal labeling strategy of hEPCs that could non-invasively track them after transplantation in hind limb ischemia models. First, hEPCs were treated with tetraacylated N-azidomannosamine (Ac4ManNAz) for generating unnatural azide groups on the hEPCs surface. Second, near-infrared fluorescence (NIRF) dye, Cy5, conjugated dibenzocylooctyne (DBCO-Cy5) was chemically conjugated to the azide groups on the hEPC surface via copper-free click chemistry, resulting Cy5-hEPCs. The bioorthogonally labeled Cy5-hEPCs showed strong NIRF signal without cytotoxicity and functional perturbation in tubular formation, oxygen consumption and paracrine effect of hEPCs in vitro. In hind limb ischemia models, the distribution and migration of transplanted Cy5-hEPCs were successfully monitored via fluorescence molecular tomography (FMT) for 28 days. Notably, blood reperfusion and therapeutic neovascularization effects were significantly correlated with the initial transplantation forms of Cy5-hEPCs such as 'condensed round shape' and 'spread shape' in the ischemic lesion. The condensed transplanted Cy5-hEPCs substantially increased the therapeutic efficacy of hind limb ischemia, compared to that of spread Cy5-hEPCs. Therefore, our new stem cell labeling strategy can be used to predict therapeutic efficacy in hind limb ischemia and it can be applied a potential application in developing cell therapeutics for regenerative medicine.

     

     

    Affiliations

    Seungho Lim  1 , Hong Yeol Yoon  2 , Soon-Jung Park  3 , Sukyung Song  4 , Man Kyu Shim  2 , Suah Yang  5 , Sun-Woong Kang  6 , Dong-Kwon Lim  7 , Byung-Soo Kim  8 , Sung-Hwan Moon  9 , Kwangmeyung Kim  10
    1 School of Chemical and Biological Engineering, Seoul National University, 1, Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), 5, Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, Republic of Korea.
    2 Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), 5, Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, Republic of Korea.
    3 Stem Cell Research Institute, T&R Biofab Co. Ltd, Sangidaehak-ro 237, Siheung-si, Gyeonggi-do, 540, Republic of Korea.
    4 Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), 5, Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, Republic of Korea; Division of Biotechnology, College of Life Sciences and Biotechnology, Korea University, 145, Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.
    5 Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), 5, Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, Republic of Korea; KU-KIST Graduate School of Converging Science and Technology, Korea University, 145, Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.
    6 Next-generation Pharmaceutical Research Center, Korea Institute of Toxicology, 141, Gajeong-ro, Yuseong-gu, Daejeon, 34114, Republic of Korea.
    7 KU-KIST Graduate School of Converging Science and Technology, Korea University, 145, Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.
    8 School of Chemical and Biological Engineering, Seoul National University, 1, Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
    9 Stem Cell Research Institute, T&R Biofab Co. Ltd, Sangidaehak-ro 237, Siheung-si, Gyeonggi-do, 540, Republic of Korea. Electronic address: sunghwanmoon@tnrbiofab.com.
    10 Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), 5, Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, Republic of Korea; KU-KIST Graduate School of Converging Science and Technology, Korea University, 145, Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea. Electronic address: kim@kist.re.kr.

  • 키워드
    Bioorthogonal click chemistry; Endothelial progenitor cells; Fluorescence molecular tomography; Ischemia treatment; Metabolic glycoengineering.
  • 덧글달기
    덧글달기
       IP : 18.220.16.184

    등록